AstraZeneca PLC
http://www.astrazeneca.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AstraZeneca PLC
Global First Approval For Daiichi’s EZH1/2 Inhibitor Valemetostat In Japan
Japan has granted to the first approval worldwide to Daiichi Sankyo’s dual EZH1/2 inhibitor valemetostat, for the treatment of adult T-cell leukemia/lymphoma. Taisho’s trivalent anti-TNFα nanobody ozoralizumab also received its global first approval, as part a large new batch of regulatory nods in the country.
Cage Fighting: Novel Drugs From MNCs, Chinese Rivals Compete In China Reimbursement Sector
After slashing the prices of their blockbuster drugs to gain wider patient access through China's main reimbursement program, multinationals are now beginning to face increasing challenges from local competitors.
Biohaven’s Non-Migraine Portfolio Takes Another Hit As Verdiperstat Fails In ALS
Pfizer is buying Biohaven's migraine portfolio, but the rest of the pipeline is poised to be spun out and there have been two development setbacks. Despite verdiperstat's failure in ALS, the field had a same-day win with Amylyx's Relyvrio approval.
Why Tessera Believes Its Gene Writing Platform Can Go Way Beyond CRISPR
As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alexion Pharmaceuticals Inc.
- Almirall Sofotec
- AlphaCore Pharma
- Amplimmune, Inc.
- Ardea Biosciences, Inc.
- Arrow Therapeutics
- Aviron
- Cellective Therapeutics, Inc.
- Definiens
- IntraBiotics Pharmaceuticals, Inc.
- KuDOS Pharmaceuticals Ltd.
- Medimmune
- Novexel
- Omthera Pharmaceuticals
- Pearl Therapeutics
- Spirogen Ltd.
- U.S. Bioscience
- Acerta Pharma
- ZS Pharma